Development of Pyridothiophene Compounds for PET Imaging of α‐Synuclein
Anna Pees, Junchao Tong, Saritha Birudaraju, Yogeshkumar S. Munot, Steven H. Liang, Dinahlee Saturnino Guarino, Robert H. Mach, Chester A. Mathis, Neil Vasdev
Abstract
Abstract Aggregated α‐synuclein (α‐syn) protein is a pathological hallmark of Parkinson's disease (PD) and Lewy body dementia (LBD). Development of positron emission tomography (PET) radiotracers to image α‐syn aggregates has been a longstanding goal. This work explores the suitability of a pyridothiophene scaffold for α‐syn PET radiotracers, where 47 derivatives of a potent pyridothiophene (asyn‐44; K d =1.85 nM) were synthesized and screened against [ 3 H]asyn‐44 in competitive binding assays using post‐mortem PD brain homogenates. Equilibrium inhibition constant (K i ) values of the most potent compounds were determined, of which three had K i ′s in the lower nanomolar range (12–15 nM). An autoradiography study confirmed that [ 3 H]asyn‐44 is promising for imaging brain sections from multiple system atrophy and PD donors. Fluorine‐18 labelled asyn‐44 was synthesized in 6±2 % radiochemical yield (decay‐corrected, n=5) with a molar activity of 263±121 GBq/μmol. Preliminary PET imaging of [ 18 F]asyn‐44 in rats showed high initial brain uptake (>1.5 standardized uptake value (SUV)), moderate washout (~0.4 SUV at 60 min), and low variability. Radiometabolite analysis showed 60–80 % parent tracer in the brain after 30 and 60 mins. While [ 18 F]asyn‐44 displayed good in vitro properties and acceptable brain uptake, troublesome radiometabolites precluded further PET imaging studies. The synthesis and in vitro evaluation of additional pyridothiophene derivatives are underway, with the goal of attaining improved affinity and metabolic stability.